A notable phase II clinical study is investigating the efficacy and safety of JS201, a bispecific antibody targeting both PD-1 and TGF-β, when used in combination with the kinase inhibitor lenvatinib for SCLC refractory to prior chemotherapy and PD-L1 inhibition. Here, CD274 is linked to small cell lung carcinoma.